Clinical trial
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of…
NCT00192101 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00192101 |
|---|---|
| Title | Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes |
| Official title | Randomized Phase II Study of the Combination of Gemcitabine (Gemzar) Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines an/or Taxanes |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, cisplatin |
| Enrollment | 100 |
| Start date | Oct 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 20, 2007 |
| Countries | Saudi Arabia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: